Skip to content

H.R. 1825 · 118th Congress (2023–2025)

Right to Try Clarification Act

This bill specifies that investigational drugs that are provided via the Right to Try pathway are exempt from restrictions that would otherwise apply under the Controlled Substances Act (e.g., restrictions on the use or possession of schedule I controlled substances).

The Right to Try pathway allows drug manufacturers to provide certain investigational drugs for which a Phase I clinical trial has been completed, but that have not yet received approval from the Food and Drug Administration, directly to individuals who have imminently life-threatening diseases or conditions and who have exhausted other treatment options and are unable to participate in clinical trials.

Show official title

To clarify that the Federal Right to Try law applies to schedule I substances for which a phase I clinical trial has been completed and to provide access for eligible patients to such substances pursuant to the Federal Right to Try law.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 1825’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Earl Blumenauer (D-OR-3)
Cosponsors
4 cosponsors

4 original · 0 later

  1. Rep. Andy Biggs (R-AZ-5)· Original · Mar 28, 2023
  2. Rep. J. Luis Correa (D-CA-46)· Original · Mar 28, 2023
  3. Rep. Madeleine Dean (D-PA-4)· Original · Mar 28, 2023
  4. Rep. Nancy Mace (R-SC-1)· Original · Mar 28, 2023
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Mar 28, 2023 – Apr 7, 2023
    1. Referred to committee

      Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Mar 28, 2023
  2. HouseHealthReferred Apr 7, 2023
  3. HouseJudiciaryReferred Mar 28, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Right to Try Clarification Act

    Display title, Short title · Introduced in House

  2. To clarify that the Federal Right to Try law applies to schedule I substances for which a phase I clinical trial has been completed and to provide access for eligible patients to such substances pursuant to the Federal Right to Try law.

    Official title · Introduced in House